Nektar data suggests it could play pivotal role in cancer, says Canaccord. Canaccord analyst Arlinda Lee said data for Nektar’s NKTR-214+Opdivo continues to show promise and she believes it is indicative of having a central role in cancer therapy with its broad mechanism of expanding and activating T-effector cells and efficacy. She reiterated her Buy rating and $94 price target on Nektar shares, which fell nearly 42% to $52.57 yesterday.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.